Adocia's ultra-fast acting insulin lispro meets in Phase IIa trial

Adocia S.A. (Euronext:ADOC) said a single dose of BioChaperone Lispro met the primary endpoint of increasing the rate of early insulin exposure from 0-30 minutes vs. Humalog insulin lispro from Eli Lilly and Co. (NYSE:LLY) in a Phase IIa trial to treat Type I diabetes (p<0.0001). The double-blind, crossover trial enrolled 36 Type I diabetics. This quarter, Adocia plans to start a dose-response Phase IIa trial with BioChaperone Lispro, with data expected before year end.

BioChaperone Lispro is an ultra-fast acting formulation of insulin lispro using BioChaperone polymer technology. Last year, Adocia and Lilly mutually terminated a 2011 deal to develop and commercialize a version of Lilly's Humalog that uses Adocia's BioChaperone technology. Adocia retained IP developed under the deal. ...